Results note: First half 2016

Reig Jofre increased sales by 7% and EBITDA by 11% in the second quarter of 2016 and confirmed a firm investment policy for ongoing projects.

  • Following the decrease of 1.4% in sales and 46.3% in EBITDA in the first quarter of 2016, turnover grew by 6.6% and EBITDA by 11.1% from April to June, thus reaching 83.44 M€ and 7.43 M€ respectively in the first six months of the year.
  • By divisions, in the second quarter of the year sales of RJF Pharma (ca. 80% of total annual turnover) grew by 8.0%, compared to +0,7% in the first quarter. RJF CDMO (ca. 20% of total annual sales) grew by 0.9% compared to a decrease of 9.2% in the first quarter.
  • The company is implementing a firm investment policy to address ongoing projects of industrial and commercial growth, including increases of workforce, productive capacity and investments in R&D.
  • Debt levels kept set at around 1 time EBITDA.
  • Reig Jofre’s GSM approved, at its meeting on 23 June, a reorganization of the equity of the company, transferring part of the share capital to reserves, with the main objective of facilitating the setting up of a dividend policy in the future.

Download the full document (PDF)